Analysed SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) News Sources
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
27-05-2026
yahoo.com
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
04-06-2026
yahoo.com
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
23-06-2026
yahoo.com
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says
11-08-2026
yahoo.com
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
13-08-2026
yahoo.com
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
17-08-2026
marketbeat.com
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
17-08-2026
yahoo.com
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
25-08-2026
yahoo.com
What is the current price of SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ)?
The current price of SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) is $11.06.
SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) since the previous trading day is $0.2.
SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) since the previous trading day is 1.8416%.
What is the most recent average sentiment score for SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ)?
The most recent average sentiment score for SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ)?
The most recent sentiment for SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ) is .
SEC-8K** Filing Available For SAGIMET BIOSCIENCES INC-A (SGMT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.